Moleculin Biotech Inc [NASDAQ: MBRX] gained 21816205% or 955429.73 points to close at $955430.0 with a heavy trading volume of 21816205 shares.
It opened the trading session at $0.2832, the shares rose to $0.3118 and dropped to $0.28, the range by which the price of stock traded the whole day. The daily chart for MBRX points out that the company has recorded -83.86% loss over the past six months.
If we look at the average trading volume of 955.43K shares, MBRX reached to a volume of 21816205 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Moleculin Biotech Inc [MBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MBRX shares is $9.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MBRX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Moleculin Biotech Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 09, 2025. The new note on the price target was released on February 12, 2025, representing the official price target for Moleculin Biotech Inc stock. Previously, the target price had yet another raise to $14, while Oppenheimer analysts kept a Outperform rating on MBRX stock.
The Price to Book ratio for the last quarter was 102.19, with the Price to Cash per share for the same quarter was set at 0.55.
Trading performance analysis for MBRX stock
Moleculin Biotech Inc [MBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -55.71. With this latest performance, MBRX shares dropped by -67.70% in over the last four-week period, additionally sinking by -83.86% over the last 6 months – not to mention a drop of -82.15% in the past year of trading.
Moleculin Biotech Inc [MBRX]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -89.59%, with Return on Assets sitting at -89.59%.
Moleculin Biotech Inc [MBRX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MBRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moleculin Biotech Inc go to 37.34%.
An analysis of Institutional ownership at Moleculin Biotech Inc [MBRX]
There are presently around $10.46%, or 10.54% of MBRX stock, in the hands of institutional investors. The top three institutional holders of MBRX stocks are: ARMISTICE CAPITAL, LLC with ownership of 0.16 million shares, which is approximately 6.1339%. VANGUARD GROUP INC, holding 84418.0 shares of the stock with an approximate value of $$0.3 million in MBRX stocks shares; and VANGUARD GROUP INC, currently with $$0.12 million in MBRX stock with ownership which is approximately 1.3272%.
